A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors

Phase 1 Completed 37 enrolled GlaxoSmithKline

Non-randomizedSequentialOpen-labelTreatment

Summary

This clinical study is being conducted at two sites to determine the optimum dose, safety, and tolerability of oral daily GSK1363089 treatment in adults with solid tumors. This study is no longer recruiting subjects.

Timeline

Start: 2006-08-09
Primary completion: 2009-05-02
Completion: 2009-11-09

Publications

Shapiro GI, McCallum S, Adams LM, Sherman L, Weller S, Swann S, Keer H, Miles D, Muller T, Lorusso P. A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. Invest New Drugs. 2013 Jun;31(3):742-50. doi: 10.1007/s10637-012-9881-z. Epub 2012 Oct 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Foretinib	Small molecule	60 mg	Oral
Subject	Foretinib	Small molecule	120 mg	Oral
Subject	Foretinib	Small molecule	240 mg	Oral
Subject	Foretinib	Small molecule	480 mg	Oral
Subject	Foretinib	Small molecule	960 mg	Oral

A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors

Summary

Timeline

Publications

Drugs

Indications